<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005957</url>
  </required_header>
  <id_info>
    <org_study_id>MA20</org_study_id>
    <secondary_id>CAN-NCIC-MA20</secondary_id>
    <secondary_id>NSABP-CAN-NCIC-MA20</secondary_id>
    <secondary_id>NCCTG-CAN-NCIC-MA20</secondary_id>
    <secondary_id>RTOG-CAN-NCIC-MA20</secondary_id>
    <secondary_id>SWOG-CAN-NCIC-MA20</secondary_id>
    <secondary_id>TROG-CAN-NCIC-MA20</secondary_id>
    <secondary_id>CDR0000067938</secondary_id>
    <nct_id>NCT00005957</nct_id>
  </id_info>
  <brief_title>Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer</brief_title>
  <official_title>A Phase III Study of Regional Radiation Therapy in Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>NSABP Foundation Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Trans-Tasman Radiation Oncology Group (TROG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Central Cancer Treatment Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Radiation to the
      tumor site and surrounding area may kill more tumor cells. It is not yet known if radiation
      therapy to the breast alone following surgery is more effective than radiation therapy to the
      breast plus surrounding tissue in treating invasive breast cancer.

      PURPOSE: This randomized phase III trial is studying radiation therapy to the breast alone to
      see how well it works compared to radiation therapy to the breast plus surrounding tissue in
      treating women who have undergone surgery for early-stage invasive breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the overall survival, disease-free survival, isolated local regional
           disease-free survival, and distant disease-free survival in women with previously
           resected, early stage, invasive breast cancer treated with breast radiotherapy with or
           without regional radiotherapy.

        -  Compare the toxic effects of these regimens in these patients.

        -  Compare the quality of life of patients (in certain participating centers) treated with
           these regimens.

        -  Compare the cosmetic outcomes in patients (in certain participating centers) treated
           with these regimens.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to number
      of positive nodes (0 vs 1-3 vs more than 3), number of axillary nodes removed (&lt;10, &gt; or
      equal to 10); type of chemotherapy (anthracycline containing vs other vs none), hormonal
      therapy (yes vs no), number of axillary lymph nodes excised*, and participating center.
      Patients are randomized to one of two treatment arms.

      NOTE: * Patients with a negative sentinel node dissection with or without an axillary
      dissection will be stratified according to the total number of nodes removed

        -  Arm I: Patients undergo standard breast radiotherapy alone 5 days a week for 5 weeks in
           the absence of disease progression or unacceptable toxicity.

        -  Arm II: Patients undergo breast and regional radiotherapy 5 days a week for 5 weeks in
           the absence of disease progression or unacceptable toxicity.

      Radiotherapy in both arms begins as soon as possible after randomization. Radiotherapy must
      begin within 8 weeks after completion of adjuvant IV chemotherapy, unless radiotherapy is
      administered concurrently with chemotherapy (i.e., cyclophosphamide, methotrexate, and
      fluorouracil [CMF]), or within 16 weeks after the last breast surgery for patients treated
      with hormonal therapy alone.

      Quality of life is assessed (in patients in certain participating centers) within 2 weeks
      prior to randomization, during the last week of radiotherapy, at 3 and 9 months after
      completion of radiotherapy, and then annually until first distant disease recurrence.

      Cosmetic outcome is assessed (in patients in certain participating centers) within 2 weeks
      prior to randomization, and then at 3 and 5 years after completion of radiotherapy or until
      first distant disease recurrence.

      Patients are followed at 3, 6, and 9 months, every 6 months for 2 years, and then annually
      thereafter.

      PROJECTED ACCRUAL: Approximately 1,822 patients will be accrued for this study within
      approximately 4 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2000</start_date>
  <completion_date type="Actual">April 19, 2017</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>10 years</time_frame>
    <description>Duration of study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>10 years</time_frame>
    <description>Disease-free survival (including locoregional and distant disease)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1832</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Standard Breast Irradiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Breast Radiation plus regional radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>regional radiation therapy (to the ipsilateral supraclavicular, axillary and internal mammary nodes)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard Breast Irradiation</intervention_name>
    <description>Standard Breast Irradiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.</description>
    <arm_group_label>Standard Breast Irradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Breast Radiation plus Regional Radiation</intervention_name>
    <description>Breast Radiation plus Regional Radiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the modified wide tangent fields.</description>
    <arm_group_label>Breast Radiation plus regional radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically proven invasive carcinoma of the breast

               -  No evidence of T4, N2-3, or M1 disease prior to surgery

               -  Node positive or high-risk node negative

          -  Prior breast-conserving therapy (BCT) (e.g., lumpectomy, partial mastectomy, or
             segmental mastectomy) and axillary node dissection or sentinel node biopsy required
             and must be a candidate for breast radiotherapy after BCT

               -  Normally patients should have microscopically clear resection margins and those
                  with positive margins should undergo reexcision

               -  Patients with microscopically focally positive margins (defined as no greater
                  than 3 times high power fields) are candidates for breast radiotherapy plus a
                  boost to the lumpectomy site

               -  Patients with prior sentinel node dissection eligible if node negative, but still
                  meet high-risk criteria

                    -  If node positive, then a level I and II axillary dissection must be
                       performed

               -  No evidence of residual disease in axilla after dissection

          -  Must be treated with currently accepted adjuvant systemic chemotherapy and/or hormonal
             therapy

          -  High risk of regional and systemic recurrence due to one of the following:

               -  Pathologically positive axillary lymph nodes

               -  Pathologically negative axillary lymph nodes with one of the following:

                    -  Primary tumor greater than 5 cm

                    -  Primary tumor greater than 2 cm and less than 10 axillary lymph nodes
                       excised and one of the following:

                         -  Estrogen receptor negative

                         -  Skarf-Bloom-Richardson grade 3

                         -  Lymphovascular invasion

          -  Hormone receptor status:

               -  Estrogen and progesterone receptor status known

        PATIENT CHARACTERISTICS:

        Age:

          -  16 and over

        Sex:

          -  Female

        Menopausal status:

          -  Premenopausal or postmenopausal

        Performance status:

          -  ECOG 0-2

        Life expectancy:

          -  At least 5 years

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  SGOT and/or SGPT no greater than 3 times upper limit of normal (ULN)*

          -  Alkaline phosphatase no greater than 3 times ULN* NOTE: * Patients with laboratory
             values greater than 3 times ULN may still be eligible if no metastatic disease by
             imaging examinations

        Renal:

          -  No serious nonmalignant renal disease

        Cardiovascular:

          -  No serious nonmalignant cardiovascular disease

        Pulmonary:

          -  No serious nonmalignant pulmonary disease

        Other:

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No other serious nonmalignant disease (e.g., systemic lupus erythematosus or
             scleroderma) that would preclude definitive surgery or radiotherapy

          -  No other malignancy except:

               -  Nonmelanomatous skin cancer

               -  Carcinoma in situ of the cervix or endometrium

               -  Contralateral noninvasive breast cancer (unless prior radiotherapy to the
                  contralateral breast)

               -  Invasive carcinoma of the cervix, endometrium, colon, thyroid, or melanoma that
                  was curatively treated at least 5 years prior to study participation

          -  No psychiatric or addictive disorder that would preclude informed consent or study
             compliance

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  See Disease Characteristics

          -  Concurrent standard adjuvant chemotherapy allowed

        Endocrine therapy:

          -  See Disease Characteristics

          -  Concurrent standard adjuvant hormonal therapy allowed

        Radiotherapy:

          -  See Disease Characteristics

        Surgery:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy J. Whelan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Margaret and Charles Juravinski Cancer Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David S. Parda</last_name>
    <role>Study Chair</role>
    <affiliation>Allegheny Cancer Center at Allegheny General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julia R. White, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lori J. Pierce, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Michigan Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Boon Chua, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Peter MacCallum Cancer Centre, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura A. Vallow, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Fraser Valley Cancer Centre</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Island Cancer Centre</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 6V5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Vitalite Health Network - Dr. Leon Richard</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 8X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Health Sciences Corporation</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. H. Bliss Murphy Cancer Centre</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>AIB 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QEII Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand River Regional Cancer Centre</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2G 1G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Health Research Institute - General Division</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niagara Health System</name>
      <address>
        <city>St. Catharines</city>
        <state>Ontario</state>
        <zip>L2R 7C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Cancer Center Health Sciences</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thunder Bay Regional Health Science Centre</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University - Dept. Oncology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUQ-Pavillon Hotel-Dieu de Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, Vallis KA, White JR, Rousseau P, Fortin A, Pierce LJ, Manchul L, Chafe S, Nolan MC, Craighead P, Bowen J, McCready DR, Pritchard KI, Gelmon K, Murray Y, Chapman JA, Chen BE, Levine MN; MA.20 Study Investigators. Regional Nodal Irradiation in Early-Stage Breast Cancer. N Engl J Med. 2015 Jul 23;373(4):307-16. doi: 10.1056/NEJMoa1415340.</citation>
    <PMID>26200977</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>April 5, 2016</results_first_submitted>
  <results_first_submitted_qc>May 9, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 15, 2016</results_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Breast Irradiation</title>
          <description>radiation therapy: Standard Breast Irradiation - A dose of 5000 centigray (cGy) in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.</description>
        </group>
        <group group_id="P2">
          <title>Breast Radiation Plus Regional Radiation</title>
          <description>regional radiation therapy (to the ipsilateral supraclavicular, axillary and internal mammary nodes)
Breast Radiation plus Regional Radiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the modified wide tangent fields.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="916"/>
                <participants group_id="P2" count="916"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="908"/>
                <participants group_id="P2" count="888"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No treated</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Crossover to the other arm</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention-to-treat</population>
      <group_list>
        <group group_id="B1">
          <title>Standard Breast Irradiation</title>
          <description>radiation therapy: Standard Breast Irradiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.</description>
        </group>
        <group group_id="B2">
          <title>Breast Radiation Plus Regional Radiation</title>
          <description>regional radiation therapy (to the ipsilateral supraclavicular, axillary and internal mammary nodes)
Breast Radiation plus Regional Radiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the modified wide tangent fields.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="916"/>
            <count group_id="B2" value="916"/>
            <count group_id="B3" value="1832"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="10"/>
                    <measurement group_id="B2" value="54" spread="10"/>
                    <measurement group_id="B3" value="54" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="916"/>
                    <measurement group_id="B2" value="916"/>
                    <measurement group_id="B3" value="1832"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Duration of study</description>
        <time_frame>10 years</time_frame>
        <population>Intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Breast Irradiation</title>
            <description>radiation therapy: Standard Breast Irradiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.</description>
          </group>
          <group group_id="O2">
            <title>Breast Radiation Plus Regional Radiation</title>
            <description>regional radiation therapy (to the ipsilateral supraclavicular, axillary and internal mammary nodes)
Breast Radiation plus Regional Radiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the modified wide tangent fields.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Duration of study</description>
          <population>Intention-to-treat</population>
          <units>percentage of alive at 10 years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="916"/>
                <count group_id="O2" value="916"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="79" upper_limit="84"/>
                    <measurement group_id="O2" value="83" lower_limit="80" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>It was estimated that the actuarial five year survival of patients on the control arm of this trial would be 80% and a 5% increase in five year survival with experiment arm is clinically interesting to detect. A sample size of 1832 will ensure 80% power to detect such a difference with two-sided alpha of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.38</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>Hazard ratio (HR) estimation is for Standard Breast Irradiation arm versus Breast Radiation plus regional radiation arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Survival</title>
        <description>Disease-free survival (including locoregional and distant disease)</description>
        <time_frame>10 years</time_frame>
        <population>Intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Breast Irradiation</title>
            <description>radiation therapy: Standard Breast Irradiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.</description>
          </group>
          <group group_id="O2">
            <title>Breast Radiation Plus Regional Radiation</title>
            <description>regional radiation therapy (to the ipsilateral supraclavicular, axillary and internal mammary nodes)
Breast Radiation plus Regional Radiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the modified wide tangent fields.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival</title>
          <description>Disease-free survival (including locoregional and distant disease)</description>
          <population>Intention-to-treat</population>
          <units>percentage of disease-free at 10 years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="916"/>
                <count group_id="O2" value="916"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="74" upper_limit="80"/>
                    <measurement group_id="O2" value="82" lower_limit="79" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard Breast Irradiation</title>
          <description>radiation therapy: Standard Breast Irradiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.
Analysis of adverse events were based on the 927 patients who actually received Standard Breast Irradiation treatment. A total of 908 patients who were randomized to Standard Breast Irradiation and 19 patients who were randomized to Breast Radiation plus regional radiation actually received the Standard Breast Irradiation treatment.</description>
        </group>
        <group group_id="E2">
          <title>Breast Radiation Plus Regional Radiation</title>
          <description>regional radiation therapy (to the ipsilateral supraclavicular, axillary and internal mammary nodes)
Breast Radiation plus Regional Radiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the modified wide tangent fields.
Analysis of adverse events were based on the 893 patients who actually received Breast Radiation plus regional radiation treatment. A total of 5 patients who were randomized to Standard Breast Irradiation and 888 patients who were randomized to Breast Radiation plus regional radiation actually received the Breast Radiation plus regional radiation treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="893"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Secondary Malignancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="893"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="745" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="752" subjects_at_risk="893"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphedema</sub_title>
                <counts group_id="E1" subjects_affected="180" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="226" subjects_at_risk="893"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="353" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="343" subjects_at_risk="893"/>
              </event>
              <event>
                <sub_title>Pain due to radiation</sub_title>
                <counts group_id="E1" subjects_affected="252" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="233" subjects_at_risk="893"/>
              </event>
              <event>
                <sub_title>Joint</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="893"/>
              </event>
              <event>
                <sub_title>Skin</sub_title>
                <counts group_id="E1" subjects_affected="313" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="316" subjects_at_risk="893"/>
              </event>
              <event>
                <sub_title>Subcutaneous tissue</sub_title>
                <counts group_id="E1" subjects_affected="167" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="180" subjects_at_risk="893"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radiation dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="130" subjects_at_risk="893"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="131" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="157" subjects_at_risk="893"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="197" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="217" subjects_at_risk="893"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" subjects_affected="187" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="218" subjects_at_risk="893"/>
              </event>
              <event>
                <sub_title>Neuropathic pain</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="893"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Gynecomastia</sub_title>
                <counts group_id="E1" subjects_affected="283" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="256" subjects_at_risk="893"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="893"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="150" subjects_at_risk="893"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes/ flushes</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="893"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Timothy J. Whelan</name_or_title>
      <organization>Juravinski Cancer Centre at Hamilton Health Sciences</organization>
      <phone>1(905) 387-9495</phone>
      <email>twhelan@HHSC.CA</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

